IL6 and COVID-19: On the other hand, late therapeutic interventions to block both PD‐1 and IL‐6 signalling pathways in ICU COVID‐19 patients and severe cases may have better clinical outcomes associated with T‐cell exhaustion reversal and reduced tissue damage and systemic inflammation.39, 81, 128